Morphological profiling services for mechanism-informed screening
Turn Cell Painting and high-content imaging data into quality-controlled phenotypic signatures, interpretable relationships and testable mechanism hypotheses.
Morphological profiling extracts quantitative features from high-content images and assembles them into rich phenotypic signatures. Grouped by phenotypic similarity and linked to known biology, these signatures inform a wide range of discovery questions – from compound and target characterization to prioritization and risk assessment.
Why is morphological profiling not routinely contributing to your drug discovery projects?
High barrier to entry
Running it well demands assay, imaging, and computational expertise that few groups have end to end.
Results don't transfer
Batch effects mean profiles from different runs, sites, or instruments can’t be compared reliably without additional processing.
Fragmented, non-standardized analysis
Imaging, transcriptomic, and proteomic data differ in structure, scale, and identifiers, so they don’t align out of the box.
Hard to combine with other omics
Deep-learning embeddings are powerful but opaque, so you get a signature without a reason and phenotypes stay descriptive.
Profiles are hard to interpret
Rich data doesn’t translate easily into a biological conclusion a team can act on.
Phenotypic signatures that can really support your drug discovery
Ardigen phenAID makes morphological profiling accessible even without an in-house imaging and computational team. Our technology covers the full path from raw images to reusable insight, extracting, correcting, versioning, and storing features consistently, then applying AI models for mode of action, bioactivity, and risk predictions. Signatures stay comparable from one screen to the next, so results accumulate into one growing dataset. An AI–lab loop keeps improving that dataset as new data arrive.
The result: analysis that informs drug discovery decisions, predicting mode of action and bioactivity, and flagging off-target and safety risks early.
From images to confident project decisions
Feature extraction infrastructure
Reproducible, versioned pipelines combining state-of-the-art handcrafted and deep-learning methods, producing comparable phenotypic representations across experiments, operators, and batches.
Batch-effect correction
Scalable data management
Storage and retrieval architecture for high-dimensional feature sets, built for similarity search, compound clustering, and cross-experiment comparison at program scale.
AI phenotypic modeling layer
Models for phenotypic similarity, MoA inference, and toxicity prediction, built on harmonized, comparable feature representations.
Multimodal integration
Architecture linking image-derived phenotypes to chemical structures, and multi-omics data representations (genomic, transcriptomic, proteomic, secretomic, etc.) for multimodal analysis.
Multivariate analysis
Analytical frameworks that simultaneously model diverse biological properties, amplifying predictive power and discovery.
Where this fits in your discovery program
MoA and bioactivity prediction: phenotypic prioritization with mode-of-action hypotheses anchored to reference profiles for follow-up.
Toxicity profiling: early detection of safety risks and liabilities.
Hit identification: scoring phenotypic similarity and divergence to identify active compounds.
Target deconvolution support: identification of phenotype-to-target inference for compounds with unknown targets.
Virtual screening: finding small molecules most likely to induce a phenotype of interest.
Move from feature spaces to mechanism-connected decisions.
Concrete, reusable deliverables
Standardized, versioned feature-extraction pipelines, configured to your assay and handed over ready to run and accessible with web application, compatible with custom workflows.
A queryable phenotypic dataset, your screens standardized into high-dimensional profiles, structured for similarity search and cross-experiment comparison.
Batch-corrected profiles with accompanying QC reports and validation outputs that confirm technical variation is removed while biological signal is retained.
Trained AI models, and their outputs, for phenotypic similarity scoring, compound clustering, MoA and biological activity inference or toxicity prediction.
Image-omics linked datasets, connecting phenotypic profiles to chemical structures and other omics data.
What this changes for the discovery team
Operational
Get from images to characterized, progressable compounds faster, without setting up your own imaging and analysis stack
Scientific
Add an orthogonal, high-dimensional layer of phenotypic evidence that characterizes compounds and corroborates activity and molecular data independently.
Strategic
Make advance/kill decisions earlier and with more evidence, spend resources on the compounds most likely to progress.
Compounding
The more you run, the smarter the platform gets, models retrain on your accumulating results, so each program benefits from the last.
Frequently Asked Questions
What is the difference between morphological, image-based, and phenotypic profiling?
Morphological profiling measures cell shape and structure, and image-based profiling extracts features from microscopy images, in practice the two are synonyms. Phenotypic profiling is the umbrella term for characterizing any measurable phenotype, including image, transcriptomic, or proteomic readouts.
What is Cell Painting?
Cell Painting is a multiplexed high-content imaging assay that stains several cellular compartments (e.g., nucleus, cytoplasm, cytoskeleton) to capture morphological changes induced by compounds or genetic perturbations. Features extracted from the images become phenotypic profiles, enabling systematic, target-agnostic analysis of cell responses.
How is image-based profiling used in phenotypic drug discovery?
It can group compounds by mechanism of action, detect off-target effects, and identify bioactive compounds. Applied to patient-derived cells, it can also distinguish disease subtypes, surface biomarkers, elucidate disease mechanisms, or screen for phenotype-correcting compounds.
How does AI enhance high-content screening (HCS) and phenotypic profiling?
AI builds finer-grained profiles, speeds up data processing to raise throughput, improves sensitivity to subtle phenotypic changes, and enables real-time feedback loops.
Can phenotypic profiling predict drug toxicity?
Yes. Morphological signatures can reveal early signs of cytotoxicity or stress, often before cell death. AI models trained on this data flag compounds with off-target or toxic effects, eliminating risky candidates early and supporting safer, more selective molecules.
How does Ardigen phenAID predict bioactivity and uncover modes of action (MoA)?
Ardigen phenAID applies deep-learning models to extract features from Cell Painting or other HCS images and compares them to annotated reference profiles. By matching phenotypic similarities to known drugs, it predicts the bioactivity of new compounds and infers their likely MoA, supporting hit prioritization, target deconvolution, and hypothesis generation in early drug discovery.
Can phenotypic signatures be matched across different cell lines?
It depends on the cell lines. With the right normalization and reference anchoring it can be possible, but not always, we scope feasibility case by case.
Large scale helps but isn't required. Many engagements start with smaller proprietary screens and use public datasets like JUMP-CP for reference anchoring.
Large scale helps but isn’t required. Many engagements start with smaller proprietary screens and use public datasets like JUMP-CP for reference anchoring.
Will the outputs be auditable for research review?
Yes. Phenotypic signatures and MoA hypotheses come with traceable feature- and reference-level evidence per condition, and pipelines are reproducible end to end.
Contact
Start with clarity before scaling AI.
If your imaging data isn’t structured for cross-screen comparison, more models won’t help. They’ll just give you scores you can’t reproduce. A short Data Journey assessment tells you exactly where the integration gaps are, what to fix first, and whether AI-driven phenotypic profiling is the right next investment.
Send us a message and we will contact you back within 48 hours.
Newsletter
Become an insider
Be the first to know about Ardigen’s latest news and get access to our publications, webinars and more!